Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for ZL-1503 in Moderate-to-severe atopic dermatitis. The expected timing is based on the latest available company guidance and may change.
6/13/25- Preclinical data presented at EAACI'25. File IND by YE 2025. 12/08/25:- Dosed first participant in global Ph1/1b AD trial; trial evaluates safety, PK, efficacy. 02/26/26:- Global Ph1/1b AD study ongoing; first-in-human data expected in H2 2026. 05/07/26:- Preclinical IMMUNOLOGY2026 data show durable IL-13/IL-31Rα pathway suppression; first-in-human Ph1 data still expected H2 2026. 08/06/26:- SAD enrolled; first-human data H2 2026; MAD atopic dermatitis data H1 2027.
Verification
Confirm timing and program details against the company announcement or filing.